Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.42 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | GSR | P00390 | 2/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL26598018 | 1.00 | SLC7A5 (0.57) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL1921493 | 1.00 | SLC7A5 (0.57) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL9076 | 0.99 | SLC7A5 (0.56) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL28098884 | 0.99 | SLC7A5 (0.56) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL19712182 | 0.99 | SLC7A5 (0.56) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL19712178 | 0.99 | SLC7A5 (0.56) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL1696965 | 0.95 | SLC7A5 (0.63) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL29062530 | 0.95 | SLC7A5 (0.63) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL3513723 | 0.94 | SLC7A5 (0.65) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL530008 | 0.94 | SLC7A5 (0.65) | SLC7A5THRBITGB3ITGA2BGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1569 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746852-A1 | LIPID AGGREGATES FOR INTRAARTICULAR ADMINISTRATION | Universität Bern (CH) | 2026-05-27 | — | — | EP | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| CN-122065102-A | Electric energy quality disturbance classification method based on gram angle field and PCNN-MSA | 国网吉林省电力有限公司吉林供电公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122042248-A | Rolling bearing fault diagnosis method based on multi-sensor fusion and GAF-CNN | 广州城市理工学院 | 2026-05-15 | — | — | CN | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| EP-3600553-B1 | GLATIRAMER DEPOT SYSTEMS FOR TREATING PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS | MAPI PHARMA LTD (IL) | 2026-05-06 | — | — | EP | claimed |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20220023377-A1 | GLATIRAMER DEPOT SYSTEMS FOR TREATING PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS | MAPI PHARMA LTD. (IL) | 2022-01-27 | — | — | US | claimed |
| JP-4800481-B2 | — | — | 2011-10-26 | — | — | JP | claimed |
| US-20100298227-A1 | Treatment of autoimmune conditions with Copolymer 1 and related copolymers | President and Fellows of Harvard College and Yeda Research | 2010-11-25 | — | — | US | claimed |
| US-20080207526-A1 | Synthetic peptides and methods of use for autoimmune disease therapies | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-08-28 | — | — | US | claimed |
| EP-1098902-A4 | TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES | YEDA RES & DEV (IL) | 2002-07-24 | — | — | EP | claimed |
| EP-1105414-A2 | SYNTHETIC PEPTIDES AND METHODS OF USE FOR AUTOIMMUNE DISEASE THERAPIES | President And Fellows of Harvard College (US) | 2001-06-13 | — | — | EP | claimed |
| EP-1098902-A1 | TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2001-05-16 | — | — | EP | claimed |
| WO-2000005250-A9 | TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES | YEDA RES & DEV (IL) | 2000-10-12 | — | — | WO | claimed |
| WO-2000005250-A1 | TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES | YEDA RESEARCH AND DEVELOPMENT CO., LTD (IL) | 2000-02-03 | — | — | WO | claimed |
| WO-2000005249-A2 | SYNTHETIC PEPTIDES AND METHODS OF USE FOR AUTOIMMUNE DISEASE THERAPIES | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137680-A1 | NOVEL COMPOUNDS | CCR1, CCR4, CCR3 | PTGS1 230/4885PTGS2 698/4885SLC7A5 1772/4885 |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | CCR1, CCR2, CBR1 | PTGS1 18/4885PTGS2 63/4885SLC7A5 1616/4885 |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM5, CHRM3 | PTGS1 3098/4885PTGS2 4471/4885SLC7A5 1627/4885 |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PTGS1 53/4885PTGS2 221/4885SLC7A5 1794/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | PTGS1 4853/4885PTGS2 4845/4885SLC7A5 867/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | PTGS1 3450/4885PTGS2 3978/4885SLC7A5 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.